Last reviewed · How we verify
Deprescribing anticholinergic and sedative mediications
Deprescribing anticholinergic and sedative medications, marketed by the Centre de recherche du Centre hospitalier universitaire de Sherbrooke, holds a unique position in the healthcare market focused on reducing polypharmacy risks. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and protection against generic competition. However, the lack of revenue data and key trial results poses a primary risk, as it may affect investor confidence and market adoption.
At a glance
| Generic name | Deprescribing anticholinergic and sedative mediications |
|---|---|
| Also known as | Drug cessation or dose reduction |
| Sponsor | Centre de recherche du Centre hospitalier universitaire de Sherbrooke |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: